Compare
iSpecimen Inc. vs OneMedNet Corp vs Cannabis Bioscience International Holdings, Inc. vs MaxCyte, Inc.
| Latest fiscal year | iSpecimen Inc. ISPC | OneMedNet Corp ONMD | Cannabis Bioscience International Holdings, Inc. CBIH | MaxCyte, Inc. MXCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-05-31 | 2025-12-31 |
| Revenue | $1.93M | $1.36M | $303.0K | $33.03M |
| Revenue growth (YoY) | -79.2% | +111.4% | +21.8% | -14.5% |
| Gross margin | 1.2% (computed) | -37.0% | 86.8% | 81.2% |
| Operating margin | -465.4% | -711.3% | -139.1% | -157.1% |
| Net margin | -543.7% | -206.1% | -181.1% | -135.1% |
| Net income | -$10.49M | -$2.80M | -$548.8K | -$44.63M |
| EPS (Diluted) | -$2.28 | -$0.06 | $0.00 | -$0.42 |
| Operating cash flow | -$4.24M | -$7.50M | -$329.6K | -$34.41M |
| Free cash flow | -$4.24M | -$7.52M | n/a | -$36.18M |
| Cash & equivalents | $6.88M | $585.0K | n/a | $20.07M |
| Total assets | $9.53M | $2.15M | $31.9K | $202.51M |
| Total liabilities | $6.44M | $5.12M | $1.20M | $31.02M |
| Shareholders' equity | $3.09M | -$2.96M | -$1.16M | $171.49M |
| Return on year-end equity | -339.6% | n/a | n/a | -26.0% |
| Shares outstanding | 8.48M | 51.98M | 11.63B | 106.79M |
Revenue, most recent five fiscal years
| Fiscal year | iSpecimen Inc. | OneMedNet Corp | Cannabis Bioscience International Holdings, Inc. | MaxCyte, Inc. |
|---|---|---|---|---|
| Latest | $1.93M Ended 2025-12-31 | $1.36M Ended 2025-12-31 | $303.0K Ended 2025-05-31 | $33.03M Ended 2025-12-31 |
| 1 year earlier | $9.29M Ended 2024-12-31 | $643.0K Ended 2024-12-31 | $248.8K Ended 2024-05-31 | $38.63M Ended 2024-12-31 |
| 2 years earlier | $9.93M Ended 2023-12-31 | $1.02M Ended 2023-12-31 | $316.8K Ended 2023-05-31 | $41.29M Ended 2023-12-31 |
| 3 years earlier | $10.40M Ended 2022-12-31 | $1.15M Ended 2022-12-31 | n/a | $44.26M Ended 2022-12-31 |
| 4 years earlier | $11.14M Ended 2021-12-31 | n/a | n/a | $33.89M Ended 2021-12-31 |